USA Chris Posner, President of Esteve Pharmaceuticals LLC, the US affiliate of Spanish specialty player ESTEVE, speaks about the process of building its US affiliate from the ground up since joining in January. With an ambition to build a 1 billion USD global business (the US is expected to drive more…
France How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player which turns over around EUR 600 million annually – seems to have hit upon a solution: continuous adaptation. “What…
France Norgine is redefining what a mid-sized European specialist can achieve, shifting from its gastroenterology heritage into a broader mix of consumer health, women’s health and rare diseases. These changes are taking shape across the organisation, with France playing an important role under Cyril Tavier’s leadership, from implementing new omnichannel models…
Belgium Geert Van Hoof, founding general manager of Chiesi Belgium, shares the exciting milestones of the company’s first decade in Belgium, including their stunning year-on-year double-digit growth, their market leadership in respiratory as well as neonatology, and their growing presence in rare diseases, as well as the attractiveness of the Chiesi…
USA Three US country managers for European pharma mid-caps explain the challenges in setting up an American affiliate, as well as how best to capitalise on the abundant opportunities in the world’s biggest pharma market. For Jorge Alderete, president Americas & SVP commercial operations at Danish firm ALK, “Market access…
Europe European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma and biotech consultancy Novasecta. Focus 75…
Europe Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve and Servier outline the strategic directions in which their companies are turning and how they are planning to ensure a successful future. David Meek, Ipsen David…
Serbia Claude Broudic, general manager for Servier in Serbia, highlights the potential for business in the country, Servier’s projects for expansion in the Balkans, and the skills needed to put together a good pharma team. What were your priorities when you took over as general manager of Servier Serbia? “When looking…
Austria Barbara Fritsche-Surchat, general manager of Servier Austria, a leading innovative French company looking to bolster its global oncology presence, provides an in-depth analysis of the balancing act between pricing and market access in the Austrian healthcare system as well as how the company’s global oncology vision has influenced Austrian operations.…
Greece Stavros Theodorakis, managing director of Chiesi Greece & Cyprus and vice president of the Hellenic Association of Pharmaceutical Companies (SFEE), pinpoints the factors that successfully carried the company through the Greek crisis, while highlighting co-branding and co-promotion as the key strategies behind Chiesi’s leading position in the domestic respiratory market.…
Ireland Grünenthal Ireland’s General Manager discusses the incredible growth of the Irish affiliate over the past twelve years, their comprehensive pain portfolio, the innovation they are bringing as pain specialists to the industry, and his strategy for increasing revenues in the next five years. You were the founder of Grünenthal’s Irish…
Switzerland As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland. Head of Swiss Business Operations Maleša Ulrico Sidjanski, MSc ETH, discusses the company’s current priorities, values, and upcoming investments. What other mid-sized multinational pharmaceutical companies present in over 80…
See our Cookie Privacy Policy Here
